Canopy Growth reported net revenue of $81.2 million CAD, or $58.6 million, in its fiscal 2027 first quarter ended June 30, 2026, a 13% increase over the prior-year quarter, alongside higher gross margins, a 68% decrease in net losses and a 59% drop in adjusted EBITDA losses. Despite the improving results, the cannabis stock remains under $1 per share and has fallen 33% over the past 12 months. Two lingering issues explain the weakness: stalled U.S. legalization progress, after the Department of Justice and Drug Enforcement Administration rescheduled medical marijuana from Schedule I to Schedule III in April 2026 without the broader recreational reforms that would benefit Canopy's U.S. affiliate Canopy USA, and continued dilution, with the share count rising from 239.9 million to 423 million over the past year, largely through at-the-market equity sales in mid-2025. A separate ATM program authorized in August 2025 gives Canopy the right to raise another $200 million, which against a current market cap of $394 million could severely dilute shareholders again.
Canopy Growth CorpQ1 revenue rose 13% with higher gross margins and a 68% smaller net loss, but the stock languishes under $1 amid stalled US legalization and heavy dilution from ATM equity sales.
NVIDIA Corporation
